Indication prioritization and repositioning

Indication prioritization and drug repositioning are critical strategies in the pharmaceutical industry, offering significant advantages in therapeutic development and delivery.

Indication prioritization allows for the efficient allocation of resources, focusing on diseases with the greatest unmet medical needs, the highest market potential, or the most promising therapeutic pathways. This enhances the impact and efficiency of drug development efforts.

At Inoviem, we can fast-track the development of new treatments or reposition existing marketed drugs, identifying pathologies where a compound may be more effective. This approach unlocks the full therapeutic potential of a molecule.

Our robust methodology breathes new life into seemingly failed compounds. Through target validation, we can identify new indications, enabling rapid drug repositioning while minimizing costly development dead ends.

To achieve this, we leverage our NPOT® and LIPS® platforms, in combination with human pathological tissues from various diseases. This approach allows us to determine the most suitable pathology for repositioning a given molecule and to assess its safety and efficacy.

For example, in one of our recent publications (DOI: 10.1002/ddr.22151), we successfully applied our NPOT® technology to optimize hydroxychloroquine for lupus treatment.